Autologous tumor-infiltrating lymphocyte therapy (Fred Hutchinson Cancer Research Center)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameAutologous tumor-infiltrating lymphocyte therapy (Fred Hutchinson Cancer Research Center)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating LymphocytesCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionLymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsSkin MelanomaMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research Center
China Registration ClassN/A

Develop Information

Active CompaniesFred Hutchinson Cancer Research Center
Inactive CompaniesN/A
Active IndicationsSkin MelanomaMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A